|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MCTS1 |
Gene summary for MCTS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MCTS1 | Gene ID | 28985 |
| Gene name | MCTS1 re-initiation and release factor | |
| Gene Alias | MCT-1 | |
| Cytomap | Xq24 | |
| Gene Type | protein-coding | GO ID | GO:0001731 | UniProtAcc | Q9ULC4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 28985 | MCTS1 | LP17 | Human | Oral cavity | LP | 1.63e-06 | 1.01e+00 | 0.2349 |
| 28985 | MCTS1 | SYSMH1 | Human | Oral cavity | OSCC | 1.38e-19 | 5.88e-01 | 0.1127 |
| 28985 | MCTS1 | SYSMH2 | Human | Oral cavity | OSCC | 5.43e-39 | 1.35e+00 | 0.2326 |
| 28985 | MCTS1 | SYSMH3 | Human | Oral cavity | OSCC | 4.10e-39 | 1.19e+00 | 0.2442 |
| 28985 | MCTS1 | SYSMH4 | Human | Oral cavity | OSCC | 8.42e-07 | 2.40e-01 | 0.1226 |
| 28985 | MCTS1 | SYSMH5 | Human | Oral cavity | OSCC | 5.29e-29 | 9.27e-01 | 0.0647 |
| 28985 | MCTS1 | SYSMH6 | Human | Oral cavity | OSCC | 6.58e-19 | 7.77e-01 | 0.1275 |
| 28985 | MCTS1 | P4_S8_cSCC | Human | Skin | cSCC | 2.01e-03 | 1.01e-01 | -0.3095 |
| 28985 | MCTS1 | P5_S10_cSCC | Human | Skin | cSCC | 4.64e-07 | 1.86e-01 | -0.299 |
| 28985 | MCTS1 | P1_cSCC | Human | Skin | cSCC | 1.55e-27 | 1.03e+00 | 0.0292 |
| 28985 | MCTS1 | P2_cSCC | Human | Skin | cSCC | 3.98e-20 | 7.27e-01 | -0.024 |
| 28985 | MCTS1 | P4_cSCC | Human | Skin | cSCC | 5.92e-37 | 8.20e-01 | -0.00290000000000005 |
| 28985 | MCTS1 | P10_cSCC | Human | Skin | cSCC | 4.55e-34 | 1.12e+00 | 0.1017 |
| 28985 | MCTS1 | male-WTA | Human | Thyroid | PTC | 3.52e-26 | 2.10e-02 | 0.1037 |
| 28985 | MCTS1 | PTC01 | Human | Thyroid | PTC | 1.93e-13 | 9.44e-02 | 0.1899 |
| 28985 | MCTS1 | PTC04 | Human | Thyroid | PTC | 2.34e-07 | 1.13e-01 | 0.1927 |
| 28985 | MCTS1 | PTC05 | Human | Thyroid | PTC | 1.49e-13 | 6.35e-01 | 0.2065 |
| 28985 | MCTS1 | PTC06 | Human | Thyroid | PTC | 8.04e-21 | 5.51e-01 | 0.2057 |
| 28985 | MCTS1 | PTC07 | Human | Thyroid | PTC | 5.59e-42 | 5.24e-01 | 0.2044 |
| 28985 | MCTS1 | ATC09 | Human | Thyroid | ATC | 1.29e-12 | 3.35e-01 | 0.2871 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:007182627 | Esophagus | HGIN | ribonucleoprotein complex subunit organization | 84/2587 | 227/18723 | 1.34e-18 | 5.37e-16 | 84 |
| GO:002261827 | Esophagus | HGIN | ribonucleoprotein complex assembly | 82/2587 | 220/18723 | 2.07e-18 | 7.36e-16 | 82 |
| GO:000641320 | Esophagus | HGIN | translational initiation | 55/2587 | 118/18723 | 7.33e-18 | 2.31e-15 | 55 |
| GO:001603227 | Esophagus | HGIN | viral process | 118/2587 | 415/18723 | 3.01e-15 | 6.22e-13 | 118 |
| GO:000218320 | Esophagus | HGIN | cytoplasmic translational initiation | 19/2587 | 34/18723 | 1.01e-08 | 6.44e-07 | 19 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:19030089 | Esophagus | HGIN | organelle disassembly | 36/2587 | 114/18723 | 8.60e-07 | 3.58e-05 | 36 |
| GO:001908016 | Esophagus | HGIN | viral gene expression | 28/2587 | 94/18723 | 4.52e-05 | 1.09e-03 | 28 |
| GO:001908115 | Esophagus | HGIN | viral translation | 8/2587 | 16/18723 | 6.00e-04 | 8.41e-03 | 8 |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MCTS1 | SNV | Missense_Mutation | rs750185102 | c.5G>A | p.Gly2Asp | p.G2D | Q9ULC4 | protein_coding | deleterious_low_confidence(0) | benign(0.07) | TCGA-A1-A0SJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MCTS1 | SNV | Missense_Mutation | c.81G>T | p.Lys27Asn | p.K27N | Q9ULC4 | protein_coding | deleterious(0) | probably_damaging(0.944) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MCTS1 | SNV | Missense_Mutation | c.433N>C | p.Cys145Arg | p.C145R | Q9ULC4 | protein_coding | deleterious(0) | benign(0.239) | TCGA-A6-2684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MCTS1 | SNV | Missense_Mutation | c.491N>A | p.Gly164Asp | p.G164D | Q9ULC4 | protein_coding | deleterious(0.02) | benign(0.226) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| MCTS1 | SNV | Missense_Mutation | c.27A>C | p.Lys9Asn | p.K9N | Q9ULC4 | protein_coding | deleterious(0.03) | benign(0.267) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| MCTS1 | SNV | Missense_Mutation | novel | c.96N>T | p.Glu32Asp | p.E32D | Q9ULC4 | protein_coding | tolerated(0.28) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MCTS1 | SNV | Missense_Mutation | c.224G>A | p.Arg75Lys | p.R75K | Q9ULC4 | protein_coding | tolerated(0.44) | benign(0.203) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MCTS1 | SNV | Missense_Mutation | novel | c.141N>T | p.Lys47Asn | p.K47N | Q9ULC4 | protein_coding | deleterious(0) | possibly_damaging(0.847) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MCTS1 | SNV | Missense_Mutation | c.314T>C | p.Phe105Ser | p.F105S | Q9ULC4 | protein_coding | deleterious(0.03) | possibly_damaging(0.455) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MCTS1 | SNV | Missense_Mutation | c.398N>C | p.Val133Ala | p.V133A | Q9ULC4 | protein_coding | deleterious(0.01) | probably_damaging(0.956) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |